In a pilot experiment using six KRAS-mutant PDX models, although ulixertinib plus afatinib or copanlisib were more effective than single agent alone in curbing tumour growth (Fig. 6a), no tumour regression was observed. The gene discussed is KRAS; the disease is neoplasm.